This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.
The most recent version of the World Health Organization classification system for myeloid neoplasms and acute leukemia, published in 2016, added a number of important biomarkers and genetic alterations for the assessment of myeloid malignancies. As the list of relevant molecular markers continues to grow and new targeted therapies are approved, traditional, single-gene approaches for analyzing myeloid malignancies have become laborious and time consuming. Next-generation sequencing has emerged as the optimal solution by enabling comprehensive assessment of all relevant molecular markers in a single NGS run.
In this webinar, Dr. Nancy Carson, Head of the Division of Genetics at the Saint John Regional Hospital, will discuss her team’s experiences as one of the first labs in Canada to implement an NGS-based myeloid assay.
Dr. Carson will discuss:
- Unique considerations and applications of NGS in myeloid malignancies
- Overview of her experience with with analytical validation and implementation of the assay
- Impact of the implementation of the assay to date through case studies
- Future directions